In contrast, a meta-analysis of 17 studies on PI*MS heterozygotes has shown that, despite reduced plasma AAT levels, these subjects are not at risk of airway obstruction, COPD or greater FEV1 decline [10]. This evidence concerns the gene SERPINA1 and chronic obstructive pulmonary disease.